NCT07140211 Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis
| NCT ID | NCT07140211 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Marc Blondon |
| Condition | Venous Thromboembolism (VTE) |
| Study Type | INTERVENTIONAL |
| Enrollment | 9,200 participants |
| Start Date | 2025-10-15 |
| Primary Completion | 2030-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 9,200 participants in total. It began in 2025-10-15 with a primary completion date of 2030-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are: * compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery? * compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.
Eligibility Criteria
Inclusion Criteria: postpartum women after delivery AND ≥1 major risk factor / ≥2 minor risk factors: * Major risk factors: Emergency cesarean section ; Pre-pregnancy BMI ≥35kg/m2 ; Known low-risk thrombophilia (heterozygous factor V Leiden; heterozygous G20210 prothrombin mutation) ; Pre-eclampsia ; Pre-term delivery ; Peripartum systemic infection ; Intra-uterine growth restriction ; Pregnancy loss * Minor risk factors: Age ≥35 years ; Pre-pregnancy BMI 30.0-34.9kg/m2 ; Current smoking ; Elective cesarean section ; Postpartum hemorrhage ; Antenatal immobility Exclusion Criteria: * ≥2 doses of postpartum LMWH * Any indication for therapeutic anticoagulation * A high-risk of postpartum VTE * An increased bleeding risk * A contra-indication to heparin
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07140211 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Venous Thromboembolism (VTE). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07140211 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 9,200 participants.
Is NCT07140211 currently recruiting?
Yes, NCT07140211 is actively recruiting participants. Contact the research team at marc.blondon@hug.ch for enrollment information.
Where is the NCT07140211 trial being conducted?
This trial is being conducted at Baden, Switzerland, Basel, Switzerland, Bern, Switzerland, Geneva, Switzerland and 4 additional locations.
Who is sponsoring the NCT07140211 clinical trial?
NCT07140211 is sponsored by Marc Blondon. The trial plans to enroll 9,200 participants.